Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Transdermal anti-nausea patch available in Europe

3M Health Care : 01 October, 2013  (New Product)
A new drug delivery system is being introduced in Europe to combat nausea in patients being treated using chemotherapy
Transdermal anti-nausea patch available in Europe


The European Medicines Agency (EMA) has granted approval for ProStrakan Group to market SANCUSO (Granisetron Transdermal System) in the European Union (EU), with 3M Drug Delivery Systems acting as the manufacturer. ProStrakan begins marketing the product this month in the United Kingdom, Germany and the Netherlands. Additional European countries are expected to be added in 2014.



Initially introduced in the United States in 2008, SANCUSO is the first and only treatment for chemotherapy-induced nausea and vomiting that does not require pills or intravenous (IV) administration. The transdermal patch is applied to the upper arm and can be worn for seven days, providing continuous transdermal delivery and eliminating the need to take pills daily to control nausea and vomiting. This simple-to-use treatment has been proven effective in patients at risk for chemotherapy-induced nausea and vomiting.



“SANCUSO is a great illustration of the patient-friendly benefits of transdermal treatment,” said Jim Ingebrand, president and general manager, 3M Drug Delivery Systems. “We look forward to a continued partnership with ProStrakan to bring SANCUSO to new markets.”



3M Drug Delivery Systems is applying more than 30 years of transdermal experience and regulatory expertise to its manufacturing responsibilities for SANCUSO. The company’s cGMP compliant manufacturing and strength in global supply chain management ensure reliability and a smooth process from start to finish for manufacturing partners.



“SANCUSO is already proving to be an important option for patients in the U.S. suffering from chemotherapy-induced nausea and vomiting,” said Jamie Blackport, senior vice president of international marketing at ProStrakan. “We are excited about working together with 3M to bring this important treatment to patients in the EU.”



While ProStrakan has previously relied on a different manufacturer for the U.S. supply of SANCUSO, FDA approval is currently pending for the 3M Drug Delivery Systems manufactured product.


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo